Roivant Sciences, a biopharmaceutical company, was founded in 2014 by Vivek Ramaswamy, a young entrepreneur with a vision to transform the way drugs are discovered and developed. The company’s inception was anything but ordinary; Ramaswamy, then just 29, started Roivant from his living room, armed with a unique business model and a passion for innovation.

The company’s meteoric rise to fame began with its innovative approach to drug development. Roivant, unlike traditional pharmaceutical companies, focuses on creating ‘Vant’ companies, or subsidiary companies, each dedicated to a specific drug or disease area. This structure allows for a high degree of focus and efficiency, enabling Roivant to develop drugs at a rapid pace. The company’s first ‘Vant’, Axovant Sciences, was launched in 2015 and quickly gained attention for its work on a potential treatment for Alzheimer’s disease.

Roivant Sciences’ Net Worth in 2025

As of 2025, Roivant Sciences’ current net worth is estimated to be around $20 billion, according to the latest available information.

Roivant Sciences’ Career

Founded in 2014 by Vivek Ramaswamy, Roivant Sciences is a biopharmaceutical company known for its innovative approach to drug development. The company focuses on repurposing known drugs for new indications, aiming to bring treatments to market faster and more cost-effectively.

Roivant Sciences’ Other Ventures

In addition to its core business, Roivant Sciences has established several subsidiary companies, or ‘Vants’, each focused on a specific therapeutic area. These include Axovant for neurodegenerative diseases, Myovant for women’s health and prostate cancer, and Urovant for urological diseases.

Roivant Sciences’ Assets

Roivant Sciences’ assets include a diverse pipeline of clinical and preclinical drug candidates, as well as a significant intellectual property portfolio. The company also has a strong financial position, with substantial cash reserves to support its operations and growth.

Roivant Sciences’ Annual Income

As of 2021, Roivant Sciences reported annual revenue of approximately $350 million. The company’s revenue has been growing steadily since its inception, reflecting its expanding pipeline and commercial success.

Frequently Asked Questions about  Roivant Sciences

What is Roivant Sciences?

Roivant Sciences is a biopharmaceutical company that focuses on repurposing drugs and developing new drugs for various diseases. It was founded in 2014 by Vivek Ramaswamy and is headquartered in Boston, Massachusetts.

How does Roivant Sciences repurpose drugs?

Roivant Sciences identifies drugs that have been approved for one indication but may have potential benefits for other diseases. The company then conducts further research and clinical trials to explore these new indications. This process can potentially speed up the drug development process and reduce costs compared to developing new drugs from scratch.

What are some of the diseases Roivant Sciences is targeting?

Roivant Sciences is currently working on treatments for a variety of diseases, including but not limited to, liver diseases, dermatological conditions, and central nervous system disorders. Some of the specific diseases and conditions they are targeting include psoriasis, atopic dermatitis, and Huntington’s disease.

What is the Roivant Sciences’ net worth?

The latest estimated net worth of Roivant Sciences is around $30 billion.

Who is the CEO of Roivant Sciences?

The current CEO of Roivant Sciences is Vivek Ramaswamy, who is also the company’s founder.

What is the stock symbol for Roivant Sciences?

Roivant Sciences is listed on the Nasdaq stock exchange under the ticker symbol ROIV.

Has Roivant Sciences gone public yet?

Yes, Roivant Sciences went public in January 2021 through a merger with a special purpose acquisition company (SPAC).

What is the mission of Roivant Sciences?

The mission of Roivant Sciences is to improve the lives of patients by repurposing and developing drugs for diseases with high unmet medical needs.

Does Roivant Sciences have any partnerships or collaborations?

Yes, Roivant Sciences has partnerships and collaborations with several pharmaceutical companies and academic institutions. These partnerships aim to advance the development of new treatments and expand the company’s pipeline.

Where is Roivant Sciences headquartered?

Roivant Sciences is headquartered in Boston, Massachusetts, USA.